Phase 2 N=16 A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)
Type 1 Diabetes Mellitus
Primary: Absolute Relative Difference (ARD) — 19.1; 14.9; 21.8; 20.4 percentage of error
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=7 A Pilot Study of Robot-assisted Therapy for Post-stroke Forearm and Wrist Rehabilitation Training
Stroke
Primary: Motor Impairment of Wrist and Forearm — 23.57 Scores
Phase 1 N=56 Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions
Healthy
Primary: AUC0-∞ — 3960; 3400; 3350; 3420 ng*h/mL
Phase 2 N=31 Carvedilol for Psychostimulant Dependence
Cocaine Dependence · Cocaine Withdrawal
Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05
Phase 1 N=16 Drug Drug Interaction of BI 201335 and Tenofovir
HIV Infections
Primary: Steady-state Pharmacokinetics of AUC0-24 of Tenofovir on Day 7 and on Day 15 — 2700; 3290 ng*h/mL
N/A N=662 A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Multiple Myeloma, Neoplasms
Primary: Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type — 0; 3; 11; 0 percentage of participants
N/A N=265 PC-Based Cognitive Rehabilitation for Traumatic Brain Injury (TBI)
Traumatic Brain Injury
Primary: Performance in TBI Patients and Controls — 237.8; 231.5; 228.0; 280.0 ms — p=< 0.001
Phase 3 N=118 A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Hepatitis C
Primary: Sustained Virological Response (SVR): Plasma HCV RNA Level < 25 IU/mL — 95.3; 54.7 percentage of participants
Phase 1 N=60 Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules
Hepatitis C
Primary: Area Under the Curve of the Analyte From Time 0 to the Last Quantifiable Data Point (AUC0-tz) — 17297.157; 17216.514 ng·h/mL
Phase 1 N=32 Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
Hepatitis C
Primary: AUC0-∞ — 76500; 86900; 136000; 129000 ng*h/mL
N/A N=30 Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke
Stroke
Primary: Oxygen Consumption During Walking — 11.25; 4.46 ml/kg/min
Phase 4 N=494 A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
Nausea · Vomiting
Primary: The Percentage of Participants With No Vomiting - Overall Stage — 77.2; 72.0 Percentage of Participants — p=0.191
Phase 2 N=128 Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
Stress Disorders, Post-Traumatic
Primary: Efficacy, Measured by Change in the Clinician-Administered PTSD Scale (CAPS) Score — -26.02; -27.33 Score on a scale
Phase 2 N=17 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Adult Fibrosarcoma · Adult Leiomyosarcoma · Adult Liposarcoma
Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…
Phase 3 N=820 A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Overall Survival: Time From Randomization to Death From Any Cause — 9.8; 11.2 months — p=0.0062